DDrare: Database of Drug Development for Rare Diseases

171. ウィルソン病
［臨床試験数：50，薬物数：59（DrugBank：17），標的遺伝子数：3，標的パスウェイ数：28］

Searched query = "Wilson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 64CuCl2; ALXN1840; Acetate; Artamin 150 mg; Artamin 250 mg; BIS-CHOLINE TETRATHIOMOLYBDATE; Bis-Choline Tetrathiomolybdate; Bis-choline TETRATHIOMOLYBDATE; Bupropion; Bupropion Hydrochloride; COPPER (64CU) CHLORIDE; Celecoxib; Chloride; Choline; Copper; Cuprior; Cuprior 150 mg film-coated tablets; Cuprior 150mg film-coated tablets; D-penicillamine; D-penicillamine 150mg; D-penicillamine 250 mg; DMPS; DMSA; Galactose; Gold; Metalcaptase® 150 mg gastro-resistant tablet; Metalcaptase® 300 mg gastro-resistant tablet; NPC-02; Nitrogen; None; Once a day Trientine; PEMINE - 150 MG CAPSULE RIGIDE 50 CAPSULE; PENICILLAMINE; Penicillamine; Procedure: Fibroscan; Procedure: Functional hepatic nitrogen clearance; Procedure: Liver biopsy; Procedure: Ultrasound; SoC Therapy; Standard of Care Medications; TETA; TETA 4HCL; TETA 4HCl; TETA.4HCI; TETA.4HCl; TRIENTINE DIHYDROCHLORIDE; Tetrathiomolybdate; Trientine; Trientine dihydrochloride; Trientine dihydrochloride 300mg capsules; Trientine tetrahydrochloride; WTX101; Wilzin; ZINC ACETATE DIHYDRATE; ZINC GLUCONATE; Zinc; Zinc acetate; Zinc gluconate; Zink Natur-Drogeriet

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-000905-57-DK (EUCTR)	17/04/2019	14/03/2019	Efficacy of zinc on copper uptake in the body depending on zinc type and dose regimen measured with 64CuCl2 PET/CT-scan	Efficacy of zinc on human gut copper uptake depending on zinc type and dose regimen quantified with 64CuCl2 PET/CT-scan	Healthy volunteers (Wilson's disease) MedDRA version: 20.0;Level: LLT;Classification code 10047988;Term: Wilson's disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Trade Name: Wilzin INN or Proposed INN: Zinc acetate Trade Name: Zink Natur-Drogeriet INN or Proposed INN: Zinc gluconate Other descriptive name: ZINC GLUCONATE Product Name: 64CuCl2 INN or Proposed INN: 64CuCl2 Other descriptive name: COPPER (64CU) CHLORIDE	The Department of Hepatology and Gastroenterology, Aarhus University Hospital	NULL	Not Recruiting			Female: yes Male: yes	30	Phase 4	Denmark

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2019-000905-57-DK
(EUCTR)

17/04/2019

14/03/2019

Efficacy of zinc on copper uptake in the body depending on zinc type and dose regimen measured with 64CuCl2 PET/CT-scan

Efficacy of zinc on human gut copper uptake depending on zinc type and dose regimen quantified with 64CuCl2 PET/CT-scan

Healthy volunteers (Wilson's disease)
MedDRA version: 20.0;Level: LLT;Classification code 10047988;Term: Wilson's disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]

Trade Name: Wilzin
INN or Proposed INN: Zinc acetate
Trade Name: Zink Natur-Drogeriet
INN or Proposed INN: Zinc gluconate
Other descriptive name: ZINC GLUCONATE
Product Name: 64CuCl2
INN or Proposed INN: 64CuCl2
Other descriptive name: COPPER (64CU) CHLORIDE

The Department of Hepatology and Gastroenterology, Aarhus University Hospital

NULL

Not Recruiting

Female: yes
Male: yes

Phase 4

Denmark